TrialThe European respiratory journal2021

Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.

Alyn Morice et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.